NCT05599802View on ClinicalTrials.gov

Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants

PHASE1UnknownINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2024

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

SARS-CoV-2 variant mRNA vaccine low dose

50μg/dose

BIOLOGICAL

SARS-CoV-2 variant mRNA vaccine high dose

100μg/dose

Sponsors

Collaborators (1)

LiveRNA Therapeutics Inc.
All Listed Sponsors
collaborator

Ningbo Rongan Biological Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

LiveRNA Therapeutics Inc.

UNKNOWN

lead

AIM Vaccine Co., Ltd.

INDUSTRY

NCT05599802 - Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants | Biotech Hunter | Biotech Hunter